Safeguarding Women from Chemical Abortion Act

Summary

Removes federal approval for mifepristone when used to end an intrauterine pregnancy and makes introduction or delivery into interstate commerce of that use unlawful shortly after enactment; it also deems such labeling misbranded. Separately, it creates a new federal private right of action that lets people sue manufacturers of that drug for bodily injury or mental-health harm attributed in whole or part to its use, with recoverable compensatory and punitive damages plus attorneys' fees. The regulatory changes become effective 14 days after enactment and the new civil-liability rule becomes effective 90 days after enactment. The law also preserves an existing federal statute referenced in the text and preserves state-law remedies that provide additional relief.

• Withdraws FDA approvals for mifepristone when used to terminate intrauterine pregnancy 14 days after enactment.
• Declares mifepristone misbranded if labeling permits its use to terminate intrauterine pregnancy.
• Makes introduction or delivery into interstate commerce of the covered use a federal violation.
• Creates a federal private right of action against mifepristone manufacturers for bodily or mental-health harms.
• Allows compensatory and punitive damages plus attorneys' fees for successful plaintiffs.
• Preserves state-law remedies in addition to the new federal cause of action.
• Civil-liability provisions take effect 90 days after enactment; regulatory changes take effect 14 days after enactment.
• Affirms that the Act does not change the applicability of a cited federal criminal statute.